Objective: Medicare Part D provides formulary protections for antipsychotics but does not exempt these drugs from cost-sharing. We investigated the impact of Part D coverage on antipsychotic drug spending, adherence, and clinical outcomes among beneficiaries with varying indications for use.
T here is an urgent need to identify insurance benefit designs that promote efficiency while maintaining or improving quality of care, especially for those with severe and persistent mental disorders. The design of Medicare Part D prescription drug benefits has significant implications for patients requiring chronic and high-cost drug therapy, such as those prescribed antipsychotics for serious mental illness. To ensure access to the range of potential therapeutic agents, Medicare designated antipsychotics as 1 of 6 protected therapeutic drug classes, meaning that all drugs within the class must be included in Part D plan formularies. These protected classes, however, are subject to the substantial and complex cost-sharing requirements included in many Part D plans, which could have the unintended consequence of limiting access to these drugs for some patients. We do not know, however, whether these Part D benefit design features provide access to necessary drugs for the vulnerable populations they are intended to protect, including beneficiaries with serious mental illness who require antipsychotic drug therapy. 1 Use of and spending on antipsychotic drugs has grown rapidly over the last decade. 2, 3 In 2009, Medicare Part D spending on antipsychotics was $5.9 billion, which was second only to antihyperlipidemics in total spending. 4 Although strong clinical evidence supports the use of these drugs for conditions such as schizophrenia and bipolar disorder, there is also considerable off-label use for unapproved or controversial indications. [5] [6] [7] [8] [9] [10] The Part D program uses cost-sharing to control drug spending, but does not differentiate cost-sharing requirements by clinical indication.
Existing studies suggest that Part D cost-sharing, including the standard coverage gap that begins after beneficiaries reach an annual spending threshold ($2930 in 2012), is associated with reductions in use of some clinically necessary medications. [11] [12] [13] [14] Few studies have, however, examined the effects of Part D cost-sharing across a range of higher and lower value indications, especially within the protected drug classes, and there is limited evidence on downstream clinical outcomes. Worse clinical outcomes and increased service utilization could increase spending in Medicare Parts A and B and offset the savings in Part D associated with cost-sharing. Although the Patient Protection and Affordable Care Act (ACA) includes a provision to phase out the most controversial form of Part D cost-sharing-that is, the coverage gap-by 2020, the future of this provision remains uncertain given budgetary pressures. 15 Even if the gap is closed, substantial cost-sharing will remain in Part D plans in the form of copayments and coinsurance. These cost-sharing structures require that beneficiaries pay relatively more for brand name versus generic products, but do not differentiate on the basis of clinical indication.
The purpose of this study was to examine the effect of Part D coverage on beneficiaries receiving antipsychotic drug therapy. We compared beneficiaries who have a coverage gap with those receiving a low-income subsidy (LIS) and, as a result, do not face a gap. We focused on 3 groups as examples that vary on the basis of whether the antipsychotic treatment is central to evidence-based care. These include schizophrenia, in which antipsychotics are necessary; bipolar disorder, in which antipsychotics can be necessary, but other therapeutic options exist; and cases in which there is no clear indication for antipsychotic use (ie, beneficiaries with no mental health diagnoses). We assessed changes in antipsychotic spending, adherence, and clinical outcomes associated with Part D cost-sharing and examined variations across these groups. We hypothesized that Part D costsharing would be associated with decreases in adherence to antipsychotic drug therapy across all groups, but that the adverse clinical effects would be greatest among those with approved indications for use and fewer therapeutic alternatives. This information can help bring about improvements in Part D coverage policies, as well as in defining drug coverage for essential health benefits created in the ACA.
METHODS

Setting
This study includes beneficiaries enrolled in Medicare Advantage (MA) prescription drug plans offered by a national plan sponsor; this sponsor offered a range of MA plans, including health maintenance organizations, preferred provider organizations, and private fee-for-service plans, in many geographic regions. This study uses Part D Event files (eg, drugs dispensed, date, and days of supply); beneficiary information (eg, LIS status, risk scores); and medical claims (eg, diagnoses, hospitalizations, emergency department (ED) visits) between 2006 and 2007. The Kaiser Foundation Research Institute Institutional Review Board approved the study.
Study Population
The study includes noninstitutionalized beneficiaries with baseline antipsychotic use-that is, at least 1 antipsychotic dispensed in 2006, and at least 1 month of enrollment in 2007. We identified 3 mutually exclusive cohorts: (1) schizophrenia (ICD-9-CM 295.X); (2) bipolar disorder (ICD-9-CM 296.0, 296.1, 296.4-296.8, 301.11, 301.13); and (3) no mental health diagnoses. [16] [17] [18] We required subjects to have at least 1 inpatient or at least 2 outpatient diagnoses in 2006 or 2007 for schizophrenia or bipolar disorder; subjects with both schizophrenia and bipolar disorder diagnoses were classified in the schizophrenia group. We excluded beneficiaries with other mental health diagnoses (eg, depression, anxiety) without concurrent diagnoses of schizophrenia or bipolar disorder to focus on populations with more definitive clinical evidence regarding the appropriateness of antipsychotic use. We categorized the remaining subjects without any of these indications as having no mental health diagnoses. We also excluded beneficiaries with dementia diagnoses because of the complexity in determining more versus less appropriate antipsychotic use in dementia using claims data. 19, 20 The list of excluded diagnoses (ICD-9-CM codes) is available in the online appendix (Table A1 , Supplemental Digital Content 1, http://links. lww.com/MLR/A482).
We examined outcomes in 2007 and beneficiaries who disenrolled or died were excluded from the cohort. We included individual MA beneficiaries enrolled in plans with a full coverage gap between $2400 in total drug spending and $3850 in out-of-pocket spending in 2007. We also included beneficiaries receiving the LIS with a full premium subsidy; these subsidies reduce standard cost-sharing requirements and eliminate the gap.
Drug Spending and Adherence
We examined monthly total and out-of-pocket spending on all Part D drugs and for antipsychotics in 2007. Total drug spending includes the drug acquisition cost and dispensing fees. Out-of-pocket costs include copayments and the full price during uncovered periods. To measure monthly adherence to antipsychotics, we calculated the proportion of days covered (PDC) by summing the days of supply of any antipsychotic dispensed in each month, allowing for carryover of remaining supply, and dividing by the total number of days in the month.
This system classifies events on the basis of ICD-9-CM diagnoses into 15 general categories of mental health conditions. We assessed time to each hospitalization or ED visit for all diagnoses and for mental health and non-mental health diagnoses separately.
Analyses
We focused on differences in outcomes in months before and after beneficiaries reached the coverage gap threshold of $2400 in total drug spending. We examined these differences among beneficiaries with a gap who reached it and a comparison group of LIS beneficiaries with similar drug spending (ie, >$2400), but who did not experience a gap in coverage, that is, a difference-in-difference approach, to account for secular changes in our outcomes. To examine changes in drug spending and adherence (PDC), we used linear fixed effects regression models (xtreg, fe in Stata 10) to account for time invariant differences between beneficiaries with and without a gap. We focused on the time period beginning 30 days after reaching the gap threshold, after which beneficiaries would have been more likely to have exhausted any existing drug supply from fills dispensed at or before the point of reaching the gap. The models included indicators for reaching the gap threshold and interactions with an indicator for having a gap versus no gap. We also modeled monthly changes in adherence before and after reaching the gap threshold by including monthly indicators and interactions with the gap indicator. Time invariant covariates, such as age, sex, and baseline risk score, drop out of the model. Because subjects face little costsharing during the catastrophic coverage period, we censored observations during the catastrophic coverage period (ie, after cumulative out-of-pocket spending reached $3850) for subjects who reached it; otherwise, subjects were followed until the end of the year.
To examine time to repeated clinical events we used the Andersen-Gill extension of the Cox model. 22 The Andersen-Gill Cox model allows for the analysis of time to repeated events (such as hospitalizations or ED visits) accounting for correlation in repeated outcomes within individuals. For each diagnostic group, we analyzed the gap and LIS groups separately; these models included a time-varying indicator for reaching the gap threshold, as defined above. We also adjusted for sex, age (40-64, 65-74, 75+, vs. less than 40 y), and the Part D (RxHCC) risk score, which is a summary score calibrated to predict current year drug spending based on prior year diagnoses. We adjusted confidence intervals (CI) for multiple comparisons using the Bonferroni correction.
RESULTS
A substantial number of subjects were under 65 years of age because they qualified for Medicare due to a disability ( Table 1 ). The proportion of younger, disabled beneficiaries was greater among LIS with no gap versus non-LIS beneficiaries with a gap, and among beneficiaries with schizophrenia or bipolar disorder versus no mental health diagnoses. Mean comorbidity levels followed a similar pattern, as measured by Part D risk scores. Overall, 47% of beneficiaries with a gap reached it, and 11% exited and reached the catastrophic coverage period; the frequency varied across diagnostic groups.
Antipsychotic Spending
For beneficiaries with a gap compared with LIS beneficiaries with no gap, total Part D and antipsychotic spending decreased after reaching the gap threshold, and the magnitude varied by indication: that is, antipsychotic spending for schizophrenia: À $123, 95% CI [À $138, À $108]; bipolar disorder: À $93 [ À $105, À $82]; and no mental health diagnosis: À $36 [À $48, À $24] ( 
Adherence
Among beneficiaries with a gap who reached it, baseline (pregap) levels of adherence were highest among beneficiaries with schizophrenia (PDC = 78.5%) compared with beneficiaries with bipolar disorder (59.2%) and without mental health diagnoses (63.2%) (mean pregap spending and adherence levels are available in the online appendix Table A2 , Supplemental Digital Content 2, http://links. lww.com/MLR/A483). On average, the PDC by antipsychotics decreased for beneficiaries with a gap versus no gap after reaching the gap threshold by 20.6 percentage points [ À 22.3, À 18.9] for beneficiaries with schizophrenia, 18.1 percentage points [À 20.0, -16.2] for beneficiaries with bipolar disorder, and 11.0 percentage points [ À 13.4, À 8.5] for beneficiaries without mental health diagnoses ( Table 2 ). Monthly differences in PDC for beneficiaries with a gap versus no gap in each diagnostic group, for the 5 months before and after reaching the gap threshold, mirror the above findings and illustrate that drug use before reaching the gap threshold was stable ( Fig. 1 ).
Clinical Events
Among beneficiaries with schizophrenia or bipolar disorder with a gap, there was an increase in hospitalizations overall after experiencing cost-sharing increases in the gap, largely attributable to increases in mental health hospitalizations [eg, hazard ratio (HR) = 1.32, 99.5% CI [1.06, 1.65] and HR = 1.29 [1.02, 1.64], respectively, for beneficiaries with schizophrenia] (Table 3) . Similarly, among beneficiaries with bipolar disorder, ED visits overall and for mental health diagnoses also increased significantly after reaching the gap (eg, HR = 1.17 [1.00, 1.37] and HR = 1.35 [1.10, 1.66], respectively). Hospitalizations and ED visits did not increase among subjects without mental health diagnoses or among LIS beneficiaries with no gap.
DISCUSSION
We studied the effects of Part D cost-sharing on drug spending, adherence, and clinical events, among beneficiaries receiving antipsychotic drugs for a range of indications. Total drug spending decreased as cost-sharing increased in the gap, in part because of reduced use of antipsychotics. Although use decreased across all groups, the largest declines were among beneficiaries for whom antipsychotic use most likely represented medically necessary, evidence-based care-that is, those with schizophrenia and bipolar disorder. Indicators of clinical harm associated with interruptions in therapy were greatest for these populations as well. Importantly, the Part D program attempted to protect access to antipsychotics by requiring inclusion in plan formularies; failure to consider other benefit design factors, namely costsharing, resulted in poor beneficiary access.
The reductions in drug use, particularly among beneficiaries with severe and persistent mental disorders, raise questions about the effects of these coverage policies on health outcomes and net medical expenditure. 23 Previous work has found increases in hospitalizations and other medical costs associated with reductions in antipsychotic drug adherence among patients with schizophrenia and bipolar disorder. 16, [24] [25] [26] Consistent with this literature, we found that mental health hospitalizations increased for beneficiaries with schizophrenia and bipolar disorder during the gap. Rates of mental health ED visits also increased To examine changes in drug spending and adherence (proportion of days covered), we used linear fixed effects regression models (xtreg, fe in Stata 10). Because the average days of supply of an antipsychotic prescription was 30 days, we examined separately the first month after reaching the gap (transition period), and Z31 days after reaching the gap; these tables report the posttransition period, after beneficiaries would have been more likely to have exhausted any existing drug supply from fills dispensed before or at the point of reaching the gap. The models included indicators for these 2 gap periods and interactions between these indicators and an indicator for having a coverage gap versus no gap due to the LIS. We censored outcomes during the catastrophic coverage period for subjects who reached it. Mean values of the outcomes during the pregap period are available in the online appendix (A2) (Supplemental Digital Content 2, http://links.lww.com/MLR/A483). CI indicates confidence interval; Diff, difference; LIS, low-income subsidy. significantly for beneficiaries with bipolar disorder. In contrast, we did not find similar evidence of increased clinical events among beneficiaries with unclear indications for antipsychotics (ie, those with no mental health diagnoses) or among LIS beneficiaries who did not face a gap. Preliminary estimates of changes in net medical expenditure during the gap, on the basis of average unit costs, suggest that increases in hospitalization and ED spending could offset savings in pharmacy costs associated with the coverage gap among beneficiaries with schizophrenia and bipolar disorder, but not among those without mental health diagnoses (online appendix Table A3 , Supplemental Digital Content 3, http://links.lww.com/MLR/A484). There could also be cumulative effects associated with poor adherence not captured in these estimates, especially to the extent that changes in disorder control lead to worsening functional and economic status, such as with employment loss.
There also were increases in adverse clinical events among beneficiaries with bipolar disorder who had other, often less expensive, therapeutic options (eg, lithium, anticonvulsants). In supplemental analyses (online appendix Table A4 , Supplemental Digital Content 4, http://links. lww.com/MLR/A485), the increases in cost-sharing because of the coverage gap were also associated with decreased use of the potential substitutes for antipsychotics, on average. In some cases, the alternatives could have been previously Changes in adherence to antipsychotics before and after reaching the gap threshold. We used linear fixed effects regression models (xtreg, fe in Stata 10) to examine changes in the monthly PDC (proportion of days covered) by any antipsychotic in the 5 months before and after reaching the coverage gap threshold ($2400 in total drug spending); changes are relative to the month before reaching the coverage gap (month 1). Beneficiaries with no gap receive the low-income subsidy (LIS) that reduces cost-sharing and eliminates the gap. poorly tolerated or antipsychotics could have been prescribed in combination with a mood stabilizer and/or anticonvulsant when individual drug regimens were not adequately effective. 27, 28 Such determinations are difficult to make using claims data and are difficult to incorporate into the design of insurance benefits. Beneficiaries may have also had limited awareness of these alternatives or limited ability to pay for all of their medications during the gap. 29 Thus, greater access protections are needed, particularly in clinical areas with substantial treatment response heterogeneity or high levels of patient vulnerability.
Taken together, these findings suggest that greater costsharing for specific patients likely advance neither efficiency nor quality and safety goals of the Part D program. Starting 2011, Medicare beneficiaries began receiving a 50% discount for brand name drugs during the gap, as mandated by the ACA; generic drugs were covered at 7%. Additional coverage will be phased in until 2020, after which, beneficiaries will pay 25% of the total cost. These decreases in out-of-pocket costs could mitigate some cost-related reductions in use across all indications, and adverse clinical effects could be less, especially among those with strong indications for antipsychotic drug therapy. Beneficiaries requiring high-cost drug therapy, such as atypical antipsychotics, will, however, continue to face substantial out-of-pocket costs throughout the gap phase-out period, and even after its closure considerable cost-sharing will remain in Part D plans. In addition, given fiscal pressures, some proposals would repeal the closure of the coverage gap 15 ; closing the gap is estimated to cost $42.6 billion dollars between 2010 and 2019. 30, 31 Our findings suggest that cost-sharing creates powerful patient incentives that need to be better aligned with clinical goals and evidence. Neither the current Part D formulary protections nor cost-sharing requirements accounts for the diagnostic indication associated with the prescription. These questions about what care is covered and who pays what portion of the cost of that care represent fundamental issues in the design of health insurance and have important implications for determining essential health benefits. 32 Newer approaches, such as value-based insurance design, attempt to align patient costs with clinical need. 33, 34 Eliminating costsharing could be desirable for patients with clear, evidencebased indications for drug use, such as antipsychotic drug therapy for patients with schizophrenia or bipolar disorder. Alternatively high cost-sharing levels could be effective for reducing spending with few or even decreasing adverse effects if applied to uncertain or dubious indications, particularly in cases when the costs of therapy are substantial or when serious side effects are associated with use. For example, use of atypical antipsychotics is associated with metabolic side effects, such as weight gain, increased risk of diabetes, and hyperlipidemia. 9, 10, [35] [36] [37] More thoughtful clinical tailoring of benefit designs could help preserve access to necessary care and discourage less-necessary care; it could also be less expensive than alternatives such as broadly filling-in the coverage gap.
This study focused on a single drug class; effects could vary in other drug classes-for example, with a different mix of indications, costs, or therapeutic options. Nevertheless, antipsychotics represent an important class from a policy perspective given their status as a protected class and the high levels of spending on these drugs by Medicare. Generic versions of several second generation antipsychotics are becoming available now, which could mitigate the adverse effects of higher cost-sharing for some beneficiaries. However, given the high level of therapeutic tailoring in these populations, the need to protect access to a wide range of therapeutic options will persist. To examine time to hospitalizations and ED visits we used the Anderson-Gill extension of the Cox model; we fit separate models for the Gap and No Gap groups. These models include a time-varying indicator for being in the first 30 days of reaching the gap threshold (transition period) and being Z31 days from the gap threshold; the models also adjust for sex, age, and the Part D (RxHCC) risk score. These tables present hazard ratios (HR) for being Z31 days from reaching the gap threshold versus pregap threshold. In sensitivity analyses we adjusted for the CMS-HCC risk scores, which predict spending in Parts A and B, instead of the RxHCC score; conclusions were the same. CI indicates confidence interval; ED, emergency department; LIS, low-income subsidy; MH, mental health.
This study was conducted among beneficiaries enrolled in MA plans and may not generalize to beneficiaries in standalone Part D plans; however, these plans were located in multiple geographic areas and included a range of delivery systems. Utilization management requirements could also vary across plans; MA plans have greater incentives to structure benefits to minimize utilization and spending in Parts A and B compared with stand-alone plans. In these MA plans, there were no prior authorization or step therapy requirements for antipsychotics in 2007; thus findings from this study isolate the effects of cost-sharing in the absence of other utilization restrictions. 38, 39 Adherence was measured using dispensing data. Although this method has been validated in previous studies, [40] [41] [42] it can be less sensitive over shorter follow-up periods (eg, those that are shorter than the average days of supply for a dispensed medication). Thus, we conducted sensitivity analyses of adherence limited to subjects with at least 90 days of follow-up after reaching the gap threshold; results were the same.
This was a nonrandomized study, and there are likely to be unmeasured differences between beneficiaries with and without a gap because of the LIS. To mitigate these concerns, we focused on fixed effects analyses that are robust to time-stable confounders, the type most likely to be present in this study, and focus on relative changes within each group before and after the gap threshold within a relatively short time frame. Nevertheless, differences between the groups could still bias our results. For example, LIS beneficiaries are more likely to qualify for Medicare because of permanent disabilities and also have higher comorbidity risk scores and drug spending. Factors such as greater polypharmacy, functional limitations, and disease severity could contribute to differences in proclivity to adhere to medications or of experiencing adverse clinical events compared with non-LIS beneficiaries. These differences, however, are likely to bias our analyses toward finding fewer differences between LIS and non-LIS beneficiaries. Importantly, we found similar trends in adherence ( Fig. 1 ) and spending (not shown) in months before the gap threshold in the 2 groups. In addition, we conducted sensitivity analyses in which we stratified LIS and non-LIS beneficiaries by disability status and found similar effects across the disabled and aged populations.
In conclusion, Part D cost-sharing was associated with reductions in use of antipsychotic drugs, 1 of 6 drug classes receiving special formulary protections under Part D. For beneficiaries with clear diagnostic indications for these drugs, mental health-related hospitalizations and ED visits also increased. Although the ACA closes the coverage gap by 2020, beneficiaries will continue to face substantial costsharing through copayments and coinsurance in most Part D plans. Future benefit designs should account for out-of-pocket costs in the consideration of access and should align these costs better with clinical goals.
